Mayo Clinic College of Medicine, Rochester, MN, USA.
Aliment Pharmacol Ther. 2010 Jun;31(11):1237-47. doi: 10.1111/j.1365-2036.2010.04288.x. Epub 2010 Mar 6.
Rome III incorporates changes in the definition of functional gastrointestinal disorder that involve a 3-month recall time for symptoms, rather than 1-year.
To validate a new version of the Talley-Bowel Disease Questionnaire (Talley-BDQ) and assess the impact of recall time period on the prevalence of symptoms.
A sample of community residents were randomly mailed a survey using 1-year (n = 396) or 3-month recall period (n = 374). We evaluated the reliability and the concurrent validity of the two versions of the questionnaire. The proportions of subjects reporting symptoms in the two versions were compared.
The median (IQR) kappa on symptom-related questions was 0.70 (0.57-0.76) from the 1-year version and 0.66 (0.56-0.77) from the 3-month version. A median kappa of 0.39 (0.19-0.70) and 0.58 (0.39-0.73) was observed for concurrent validation of the 1-year and 3-month versions respectively. Except for gastro-oesophageal reflux symptoms, no differences were observed on the prevalence of clinically relevant symptoms.
The revised Talley-BDQ is reliable, with excellent reproducibility and validity. There were few differences in reported symptom rates between the 3-month and 1-year recall time versions of the questionnaire. A 1-year recall time may more efficiently capture infrequent or subtle symptoms.
罗马 III 纳入了功能性胃肠病定义的变化，涉及症状的 3 个月回顾时间，而不是 1 年。
验证新的塔利-肠病问卷（Talley-BDQ）版本，并评估回忆时间对症状发生率的影响。
采用 1 年回顾期（n=396）和 3 个月回顾期（n=374），对社区居民进行随机邮件问卷调查。我们评估了两种问卷版本的可靠性和同时效度。比较了两种版本报告症状的受试者比例。
1 年版本中症状相关问题的中位数（IQR）kappa 值为 0.70（0.57-0.76），3 个月版本为 0.66（0.56-0.77）。1 年和 3 个月版本的同时效度验证中位数 kappa 值分别为 0.39（0.19-0.70）和 0.58（0.39-0.73）。除胃食管反流症状外，两种回忆时间版本的临床相关症状的发生率均无差异。
修订后的塔利-肠病问卷可靠，具有极好的可重复性和有效性。问卷的 3 个月和 1 年回顾时间版本之间报告的症状发生率差异较小。1 年回顾时间可能更有效地捕捉不频繁或微妙的症状。
